Columbia University • Taub Institute
Clinical Trials
REFLECT 3: Effects of Rosiglitazone-XR on Mild-to Moderate Alzheimer’s Disease
We are seeking English and Spanish-speaking men and women, ages 50-90, to participate in a Phase III study to determine the effectiveness of Rosiglitazone-XR on cognitive function and clinical response in patients diagnosed with Alzheimer’s disease. Participants must have been on standard cholinesterase therapy for 6 months and have a family member or caregiver who can attend appointments during the research study. For more information, please contact Sarah Downs at 212-305-2077.
Safety and Effi cacy of AC-3933 in Mild to Moderate Alzheimer’s Disease
We are seeking men and women age 55 or older with mildto- moderate Alzheimer’s disease to participate in a Phase II study using the investigational drug, AC-3933. Each participant must have a family member or caregiver who can attend appointments during the research study. If interested, please contact Evelyn Dominguez at 212-305-2371.
Study to Improve Sleep in Alzheimer’s Disease Patients
We are seeking men and women, age 55 and older with mild to moderate Alzheimer’s disease to participate in a 8-week study to determine the effectiveness, safety, and tolerability of Rozerem in treating sleep disturbances. All participants must have a family member or caregiver to accompany them to study visits. For more information, please contact Ruth Tejeda at 212-305-7661.
Valproate in Dementia (VALID) Study
We are seeking English and Spanish-speaking men and women between 55 and 90 years of age to participate in a study to determine whether Valproate (a standard anticonvulsant medication) is effective in delaying or preventing the development of difficult behaviors such as agitation or psychosis in people with Alzheimer’s disease (AD). This study will also determine whether Valproate slows the progression of AD. Participants must have a diagnosis of AD and have not experienced agitation or psychosis since the onset of the AD. If interested, please contact Ruth Tejeda at 212-305-7661.
Antipsychotic Medication Treatment of Psychosis and Behavioral Dyscontrol in Alzheimer’s Disease Study
This research study, funded by the National Institute of Aging, uses risperidone (an FDA-approved antipsychotic medication) to treat people with Alzheimer’s disease who suffer from hallucinations, delusions, agitation, and/or aggression. Treatment continues over a period of 48 weeks. Each eligible participant must have a family member or caregiver who can assist with adherence to treatment and provide information during the research study. For further information, please contact Michelle Motta at 212-543-6132.
Antidepressant Treatment Studies for Combined Depression and Memory Complaints
We are currently conducting medication treatment studies for individuals (age 50+) experiencing both depression and mild memory and/or concentration difficulties. The studies offer both neuropsychological testing for memory and psychiatric evaluation of mood prior to and during the period of treatment. Treatment in our clinic is provided for eligible individuals at no cost for at least 6 months. For further information, please contact Oliver Harper at 212-543-5067.
Neuroimaging Studies
Alzheimer’s Disease Neuroimaging Study
We are seeking English and Spanish-speaking men and women age 55 to 90, who have normal memory, or mild memory problems, or early Alzheimer’s disease, to participate in a study to determine whether imaging of the brain with PET or MRI scans every 6 months can help predict and monitor the onset and progression of Alzheimer’s disease. In addition to the neuroimaging, the study will collect blood and, for some participants, cerebral spinal fluid to determine if biomarkers can predict and monitor the disease. No medication will be prescribed. To participate or get more information about the study please contact, Nick Adams at 212-342-0522 or Rachel Scherer at 212-305-1987.
PET Imaging of Subjects with and without Memory Problems
We are seeking English-speaking men and women age 50 to 85, who have normal memory, mild memory problems, or early Alzheimer’s disease, to participate in a study to determine whether imaging of the brain with PET or MRI scans can help predict the onset and/or progression of Alzheimer’s disease. For further information please contact the study coordinator, Sara Rosenblum, at 212-543-5956.
Amyloid and Glucose Brain Imaging Research Study for People with and without Memory Problems
This study uses imaging procedures to understand brain changes that are related to Alzheimer’s disease. Participants receive a Positron Emission Tomography (PET) scan that uses a radioactive marker that is taken up by abnormal deposits (a.k.a. amyloid deposits), which may be related to Alzheimer’s disease. A PET glucose scan and an MRI scan, which are standard clinical procedures, are also done in this research study. These procedures are performed once at an initial visit and then again one year later. Participants are reimbursed $100 for a PET scan day and $50 for an MRI scan. For further information, please contact Katrina Cuasay at 212-543-5025.
Brain Imaging Study of Smell Function in Healthy Individuals and Patients with Memory Complaints and Alzheimer’s disease
This study uses brain-imaging procedures to understand how aging and Alzheimer’s disease affect smell function. Healthy individuals and patients with memory complaints or with Alzheimer’s disease receive a Functional Magnetic Resonance Imaging (fMRI) scan while smelling common odors (e.g., coffee). Similar to standard MRI, which looks at brain structures, fMRI uses magnetic fields and radio waves to look at how the brain is functioning. This study will help us to understand the changes that occur in brain activity with age and disease progression. For further information, please contact Matt Tabert, Ph.D., at 212-543-5046.
Other Studies
Genetic Linkage Study
We are seeking Caribbean Hispanic families for a study to identify genes that may increase the risk for Alzheimer’s disease (AD). If you have at least two living family members diagnosed with AD, please call Vincent Santana at 1-800- 243-5828 or Jennifer Williamson at 212-305-4655.
Additional Information
Brain Donation Program “Give the Gift of Knowledge”
Brain donation allows valuable information to be obtained regarding normal aging and diseases that affect memory. This information may be useful towards the goal of developing more effective treatment strategies. If you or a family member wish to learn more about this program, please call Arlene Lawton, RN at 212-305-9086.
Lucy G. Moses Center for Memory and Behavioral Disorders
Changes in memory and thinking abilities can occur from a variety of conditions, not just Alzheimer’s disease. Taub Institute specialists offer a thorough multidisciplinary evaluation of memory and thinking difficulties at two locations:
The Neurological Institute
710 West 168th Street
New York, NY 10032
and
Columbia Presbyterian Eastside
16 East 60th Street
New York, NY 10022.
For Appointments call: 212-305-6939.
NYU School of Medicine Clinical Trails>>
 Previous | Next 
| 
